Femke Eam Froklage
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Femke Eam Froklage has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Adriaan A. Lammertsma
University Medical Center Groningen, University of Groningen
3 shared publications Andrey Postnov
Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands
2 shared publicationsEsther Bakker
Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands
2 shared publications- Jaap C. Reijneveld
Stichting Epilepsie Instellingen Nederland (SEIN) Heemstede SW the Netherlands
2 shared publications Jan J Heimans
Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
2 shared publications- Patrick Schober
Department of Anesthesiology, Amsterdam UMC, Amsterdam, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 22 July 2016
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 37 (1) , 97-105
Altered GABAA receptor density and unaltered blood–brain barrier [11C]flumazenil transport in drug-resistant epilepsy patients with mesial temporal sclerosis
Studies in rodents suggest that flumazenil is a P-glycoprotein substrate at the blood–brain barrier. This study aimed to assess whether [11C]flumazenil is a P-glycoprotein substrate in humans and to what extent increased P-glycoprotein function in epilepsy may confound interpretation of clinical [11C]flumazenil studies used to assess gamma-aminobutyric acid A receptors. Nine drug-resistant patients with epilepsy and mesial temporal sclerosis were scanned twice using [11C]flumazenil before and after partial P-glycoprotein blockade with tariquidar. Volume of distribution, nondisplaceable binding potential, and the ratio of rate constants of [11C]flumazenil transport across the blood–brain barrier (K1/k2) were derived for whole brain and several regions. All parameters were compared between pre- and post-tariquidar scans. Regional results were compared between mesial temporal sclerosis and contralateral sides. Tariquidar significantly increased global K1/k2 (+23%) and volume of distribution (+10%), but not nondisplaceable binding potential. At the mesial temporal sclerosis side volume of distribution and nondisplaceable binding potential were lower in hippocampus (both ∼−19%) and amygdala (both ∼−16%), but K1/k2 did not differ, suggesting that only regional gamma-aminobutyric acid A receptor density is altered in epilepsy. In conclusion, although [11C]flumazenil appears to be a (weak) P-glycoprotein substrate in humans, this does not seem to affect its role as a tracer for assessing gamma-aminobutyric acid A receptor density.
- 22 July 2016
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 37 (1) , 97-105
Open AccessAltered GABAA receptor density and unaltered blood–brain barrier [11C]flumazenil transport in drug-resistant epilepsy patients with mesial temporal sclerosis
Studies in rodents suggest that flumazenil is a P-glycoprotein substrate at the blood–brain barrier. This study aimed to assess whether [11C]flumazenil is a P-glycoprotein substrate in humans and to what extent increased P-glycoprotein function in epilepsy may confound interpretation of clinical [11C]flumazenil studies used to assess gamma-aminobutyric acid A receptors. Nine drug-resistant patients with epilepsy and mesial temporal sclerosis were scanned twice using [11C]flumazenil before and after partial P-glycoprotein blockade with tariquidar. Volume of distribution, nondisplaceable binding potential, and the ratio of rate constants of [11C]flumazenil transport across the blood–brain barrier (K1/k2) were derived for whole brain and several regions. All parameters were compared between pre- and post-tariquidar scans. Regional results were compared between mesial temporal sclerosis and contralateral sides. Tariquidar significantly increased global K1/k2 (+23%) and volume of distribution (+10%), but not nondisplaceable binding potential. At the mesial temporal sclerosis side volume of distribution and nondisplaceable binding potential were lower in hippocampus (both ∼−19%) and amygdala (both ∼−16%), but K1/k2 did not differ, suggesting that only regional gamma-aminobutyric acid A receptor density is altered in epilepsy. In conclusion, although [11C]flumazenil appears to be a (weak) P-glycoprotein substrate in humans, this does not seem to affect its role as a tracer for assessing gamma-aminobutyric acid A receptor density.
- Open Access
- 20 August 2015
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 56 (11) , 1730-1735
Quantification of11C-Laniquidar Kinetics in the Brain
Overexpression of the multidrug efflux transport P-glycoprotein may play an important role in pharmacoresistance. 11C-laniquidar is a newly developed tracer of P-glycoprotein expression. The aim of this study was to develop a pharmacokinetic model for quantification of 11C-laniquidar uptake and to assess its test-retest variability. Methods: Two (test-retest) dynamic 11C-laniquidar PET scans were performed in eight healthy subjects. Plasma input functions were obtained using on-line arterial blood sampling with metabolite corrections derived from manual samples. Co-registered T1 MRI scans were used for region of interest definition. Time-activity curves were analysed using various plasma input compartmental models. Results: 11C-Laniquidar was metabolised rapidly with a parent plasma fraction of 50% at ten minutes post tracer injection. In addition, its first pass extraction was low. Using conventional models, 11C-laniquidar time-activity curves were best fitted to an irreversible single tissue compartment (1T1K) model. Nevertheless, significantly better fits were obtained using two parallel single tissue compartments, one for parent tracer and the other for labelled metabolites (dual input model). Robust K1 results were also obtained by fitting the first 5 minutes of PET data to the 1T1K model, at least when 60 minutes plasma input data were used. For both models, test-retest variability of 11C-laniquidar K1 was ~19%. Conclusion: Accurate quantification of 11C-laniquidar kinetics in the brain is hampered by its fast metabolism and the likelihood that labelled metabolites enter the brain. Best fits for the entire 60 minutes of data were obtained using a dual input model, accounting for uptake of 11C-laniquidar and its labelled metabolites. Alternatively, K1 could be obtained from a 5 minutes scan using a standard 1T1K model. In both cases, test-retest variability of K1 was ~19%.
- 20 August 2015
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 56 (11) , 1730-1735
Open AccessQuantification of11C-Laniquidar Kinetics in the Brain
Overexpression of the multidrug efflux transport P-glycoprotein may play an important role in pharmacoresistance. 11C-laniquidar is a newly developed tracer of P-glycoprotein expression. The aim of this study was to develop a pharmacokinetic model for quantification of 11C-laniquidar uptake and to assess its test-retest variability. Methods: Two (test-retest) dynamic 11C-laniquidar PET scans were performed in eight healthy subjects. Plasma input functions were obtained using on-line arterial blood sampling with metabolite corrections derived from manual samples. Co-registered T1 MRI scans were used for region of interest definition. Time-activity curves were analysed using various plasma input compartmental models. Results: 11C-Laniquidar was metabolised rapidly with a parent plasma fraction of 50% at ten minutes post tracer injection. In addition, its first pass extraction was low. Using conventional models, 11C-laniquidar time-activity curves were best fitted to an irreversible single tissue compartment (1T1K) model. Nevertheless, significantly better fits were obtained using two parallel single tissue compartments, one for parent tracer and the other for labelled metabolites (dual input model). Robust K1 results were also obtained by fitting the first 5 minutes of PET data to the 1T1K model, at least when 60 minutes plasma input data were used. For both models, test-retest variability of 11C-laniquidar K1 was ~19%. Conclusion: Accurate quantification of 11C-laniquidar kinetics in the brain is hampered by its fast metabolism and the likelihood that labelled metabolites enter the brain. Best fits for the entire 60 minutes of data were obtained using a dual input model, accounting for uptake of 11C-laniquidar and its labelled metabolites. Alternatively, K1 could be obtained from a 5 minutes scan using a standard 1T1K model. In both cases, test-retest variability of K1 was ~19%.
- 22 November 2013
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 116 (2) , 387-394
Central neurotoxicity of standard treatment in patients with newly-diagnosed high-grade glioma: a prospective longitudinal study
Following tumor resection, the majority of high-grade glioma (HGG) patients are treated with a combined modality regimen of radiotherapy and temozolomide. As a result of the tumor itself or as treatment-related neurotoxic side-effects, these patients may experience cognitive deficits. Additionally, radiological abnormalities expressed as white matter hyperintensities (WMH) and cerebral atrophy (CA) can develop. In this study, these functional and morphological parameters are evaluated, and their relation is investigated. After surgery, HGG patients underwent chemo-irradiation for six weeks, followed by six cycles of temozolomide. Assessments were performed before chemo-irradiation, post-concomitantly, after the third and sixth adjuvant cycle, and 3 and 7 months after treatment. Degree of WMH and CA was scored on MRI. Patients’ neuropsychological performance was compared to healthy matched controls, yielding six cognitive domain z-scores. Development or progression of pre-existing WMH and CA during follow-up was observed in 36 and 45 % of the patients (n = 39) respectively. Cognitive functioning remained stable or improved in 70 % of the patients and deteriorated in 30 % of the patients (n = 33). Of the cognitive decliners, 80 % had tumor progression within 4 months thereafter. No clear association between cognitive functioning and WMH or CA was found. Central neurotoxic effects of combined modality treatment in HGG patients expressed by radiological abnormalities are encountered in approximately 40 % of patients. However, functional impact as indexed by cognitive functioning was found to be limited. Furthermore, development or progression of pre-existing WMH and CA does not consistently result in functional impairment as measured by cognitive tests.
- 22 November 2013
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 116 (2) , 387-394
Central neurotoxicity of standard treatment in patients with newly-diagnosed high-grade glioma: a prospective longitudinal study
Following tumor resection, the majority of high-grade glioma (HGG) patients are treated with a combined modality regimen of radiotherapy and temozolomide. As a result of the tumor itself or as treatment-related neurotoxic side-effects, these patients may experience cognitive deficits. Additionally, radiological abnormalities expressed as white matter hyperintensities (WMH) and cerebral atrophy (CA) can develop. In this study, these functional and morphological parameters are evaluated, and their relation is investigated. After surgery, HGG patients underwent chemo-irradiation for six weeks, followed by six cycles of temozolomide. Assessments were performed before chemo-irradiation, post-concomitantly, after the third and sixth adjuvant cycle, and 3 and 7 months after treatment. Degree of WMH and CA was scored on MRI. Patients’ neuropsychological performance was compared to healthy matched controls, yielding six cognitive domain z-scores. Development or progression of pre-existing WMH and CA during follow-up was observed in 36 and 45 % of the patients (n = 39) respectively. Cognitive functioning remained stable or improved in 70 % of the patients and deteriorated in 30 % of the patients (n = 33). Of the cognitive decliners, 80 % had tumor progression within 4 months thereafter. No clear association between cognitive functioning and WMH or CA was found. Central neurotoxic effects of combined modality treatment in HGG patients expressed by radiological abnormalities are encountered in approximately 40 % of patients. However, functional impact as indexed by cognitive functioning was found to be limited. Furthermore, development or progression of pre-existing WMH and CA does not consistently result in functional impairment as measured by cognitive tests.
- Open Access
- 28 March 2012
- Published by Springer Nature in EJNMMI Research
- Vol. 2 (1) , 12
[11C]Flumazenil brain uptake is influenced by the blood-brain barrier efflux transporter P-glycoprotein
Background: [11C]Flumazenil and positron emission tomography (PET) are used clinically to assess gamma-aminobutyric acid (GABA)-ergic function and to localize epileptic foci prior to resective surgery. Enhanced P-glycoprotein (P-gp) activity has been reported in epilepsy and this may confound interpretation of clinical scans if [11C]flumazenil is a P-gp substrate. The purpose of this study was to investigate whether [11C]flumazenil is a P-gp substrate. Methods: [11C]Flumazenil PET scans were performed in wild type (WT) (n = 9) and Mdr1a/1b, (the genes that encode for P-gp) double knockout (dKO) (n = 10) mice, and in naive rats (n = 10). In parallel to PET scanning, [11C]flumazenil plasma concentrations were measured in rats. For 6 of the WT and 6 of the dKO mice a second, [11C]flumazenil scan was acquired after administration of the P-gp inhibitor tariquidar. Cerebral [11C]flumazenil concentrations in WT and Mdr1a/1b dKO mice were compared (genetic disruption model). Furthermore, pre and post P-gp-blocking cerebral [11C]flumazenil concentrations were compared in all animals (pharmacological inhibition model). Results: Mdr1a/1b dKO mice had approximately 70% higher [11C]flumazenil uptake in the brain than WT mice. After administration of tariquidar, cerebral [11C]flumazenil uptake in WT mice increased by about 80% in WT mice, while it remained the same in Mdr1a/1b dKO mice. In rats, cerebral [11C]flumazenil uptake increased by about 60% after tariquidar administration. Tariquidar had only a small effect on plasma clearance of flumazenil. Conclusions: The present study showed that [11C]flumazenil is a P-gp substrate in rodents. Consequently, altered cerebral [11C]flumazenil uptake, as observed in epilepsy, may not reflect solely GABAA receptor density changes but also changes in P-gp activity.
- 28 March 2012
- Published by Springer Nature in EJNMMI Research
- Vol. 2 (1) , 12
Open Access[11C]Flumazenil brain uptake is influenced by the blood-brain barrier efflux transporter P-glycoprotein
Background: [11C]Flumazenil and positron emission tomography (PET) are used clinically to assess gamma-aminobutyric acid (GABA)-ergic function and to localize epileptic foci prior to resective surgery. Enhanced P-glycoprotein (P-gp) activity has been reported in epilepsy and this may confound interpretation of clinical scans if [11C]flumazenil is a P-gp substrate. The purpose of this study was to investigate whether [11C]flumazenil is a P-gp substrate. Methods: [11C]Flumazenil PET scans were performed in wild type (WT) (n = 9) and Mdr1a/1b, (the genes that encode for P-gp) double knockout (dKO) (n = 10) mice, and in naive rats (n = 10). In parallel to PET scanning, [11C]flumazenil plasma concentrations were measured in rats. For 6 of the WT and 6 of the dKO mice a second, [11C]flumazenil scan was acquired after administration of the P-gp inhibitor tariquidar. Cerebral [11C]flumazenil concentrations in WT and Mdr1a/1b dKO mice were compared (genetic disruption model). Furthermore, pre and post P-gp-blocking cerebral [11C]flumazenil concentrations were compared in all animals (pharmacological inhibition model). Results: Mdr1a/1b dKO mice had approximately 70% higher [11C]flumazenil uptake in the brain than WT mice. After administration of tariquidar, cerebral [11C]flumazenil uptake in WT mice increased by about 80% in WT mice, while it remained the same in Mdr1a/1b dKO mice. In rats, cerebral [11C]flumazenil uptake increased by about 60% after tariquidar administration. Tariquidar had only a small effect on plasma clearance of flumazenil. Conclusions: The present study showed that [11C]flumazenil is a P-gp substrate in rodents. Consequently, altered cerebral [11C]flumazenil uptake, as observed in epilepsy, may not reflect solely GABAA receptor density changes but also changes in P-gp activity.
- 30 March 2011
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 12 (3) , 379-395
Central Neurotoxicity in Cancer Chemotherapy: Pharmacogenetic inSights
Central neurotoxicity of chemotherapy is likely to be multifactorial. There are two hypotheses regarding endogenous mechanisms that may be involved, namely the target and the blood-brain barrier transporter hypotheses. Here, we will review candidate genetic determinants for the risk of chemotherapy-induced neurotoxicity, such as polymorphisms involved in the target mechanism. These include polymorphisms in folate metabolizing enzymes and apolipoprotein E, as well as those in blood-brain barrier transporter genes. Currently, the exact role of pharmacogenetics in mechanisms that lead to central neurotoxicity of chemotherapy has not been fully unraveled. Larger, prospective, longitudinal and more uniform studies are needed, with prechemotherapy and follow-up measurements of neuropsychological performance, MRI, PET, genetic profiles and biomarkers relevant for the proposed target and transporter mechanisms.
- 30 March 2011
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 12 (3) , 379-395
Central Neurotoxicity in Cancer Chemotherapy: Pharmacogenetic inSights
Central neurotoxicity of chemotherapy is likely to be multifactorial. There are two hypotheses regarding endogenous mechanisms that may be involved, namely the target and the blood-brain barrier transporter hypotheses. Here, we will review candidate genetic determinants for the risk of chemotherapy-induced neurotoxicity, such as polymorphisms involved in the target mechanism. These include polymorphisms in folate metabolizing enzymes and apolipoprotein E, as well as those in blood-brain barrier transporter genes. Currently, the exact role of pharmacogenetics in mechanisms that lead to central neurotoxicity of chemotherapy has not been fully unraveled. Larger, prospective, longitudinal and more uniform studies are needed, with prechemotherapy and follow-up measurements of neuropsychological performance, MRI, PET, genetic profiles and biomarkers relevant for the proposed target and transporter mechanisms.